Goldman set a EUR 133 target for IMCD stock, conditions matter

Published on 10/12/2026 at 10:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

IMCD reported EUR 285 million EBITA in the first half of 2026. IMCD stock costs EUR 99.64 on October 12, 2026, 25.08 percent below the target.

Key points in brief

Goldman Sachs added IMCD to its October conviction list with a EUR 133 12-month target.
First-half 2026 EBITA reached EUR 285 million, up 8 percent on a constant-currency basis.
IMCD stock was trading at EUR 99.64 at Lang & Schwarz on October 12, 2026 at 10:00 a.m. CEST.
IMCD is scheduled to publish first nine months 2026 results on November 5, 2026.

Extreme Makroaufnahme farbiger kristalliner Chemiegranulate mit glänzenden Wassertropfen — Makroaufnahme farbiger Chemiegranulate veranschaulicht Produktvielfalt von IMCD N.V., ISIN NL0010801007, in extremer Nahansicht, Illustration mit AI erstellt.

IMCD (ISIN NL0010801007) was trading at EUR 99.64 at Lang & Schwarz on October 12, 2026 at 10:00 a.m. CEST, while CNBC reported on October 2, 2026 that Goldman Sachs had set a EUR 133 12-month target for the specialty chemicals distributor. The target is 33.48 percent above the Lang & Schwarz price, making margin recovery the central valuation question.

Goldman backs specialized chemicals

Goldman's October conviction list included IMCD alongside three other European companies, according to CNBC. Analyst Suhasini Varanasi argued that IMCD's specialized, higher-value ingredients and formulation services could make profitability gains more durable than in commodity chemicals and provide protection against Chinese competition.

The same report put the operating EBITA margin at 10.40 percent in 2025 and projected 27.00 percent for 2027. That is a 16.60 percentage-point expansion in the published outlook, but the forecast also leaves execution and demand as important conditions for the target.

First-half recovery has figures

In the first half of 2026, IMCD's FX-adjusted revenue increased 11 percent, comprising 3 percent organic growth and 7 percent from acquisitions, according to the Yahoo Finance transcript published on July 29, 2026.

EBITA rose 8 percent on a constant-currency basis to EUR 285 million in the same period, while free cash flow reached EUR 222 million and cash conversion was 76.20 percent. The comparison is constructive, yet the acquisition contribution means organic growth remains the cleaner test of underlying demand.

What does the EUR 133 target imply

At EUR 99.64, IMCD stock was 25.08 percent below Goldman's target on October 12, 2026. The gap depends on the projected margin improvement, while the first-half revenue mix shows that acquisitions supplied more growth than organic expansion.

Three dated IMCD milestones

On July 29, 2026, IMCD reported first-half EBITA of EUR 285 million, up 8 percent on a constant-currency basis, in the Yahoo Finance transcript. On the same date, management described three first-half acquisitions and EUR 50 million of acquisition spending in that transcript. On October 2, 2026, Goldman Sachs assigned IMCD a EUR 133 12-month target, as CNBC reported.

Next dates for results

According to IMCD, the company is scheduled to publish first nine months 2026 results on November 5, 2026, followed by full-year 2026 results on February 19, 2027.

Stock price and investor perspective

IMCD was trading at EUR 99.64 at Lang & Schwarz on October 12, 2026 at 10:00 a.m. CEST. The valuation case therefore rests on whether the projected operating EBITA margin can move from 10.40 percent in 2025 toward 27.00 percent in 2027 while organic growth strengthens.

The further course of trading is shown by the continuously updated real-time quote of IMCD stock.